WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326981

CAS#: 79338-84-4

Description: Benvitimod, also known as tapinarof, WB-1001; GSK-2894512 and WBI-1001, is a non-steroidal anti-inflammatory drug (NSAID) potentially for the treatment of atopic dermatitis. WBI-1001 is an efficacious novel topical anti-inflammatory molecule for the treatment of AD.

Price and Availability




Benvitimod is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 326981
Name: Benvitimod
CAS#: 79338-84-4
Chemical Formula: C17H18O2
Exact Mass: 254.1307
Molecular Weight: 254.329
Elemental Analysis: C, 80.28; H, 7.13; O, 12.58

Synonym: Benvitimod; WB-1001; WBI-1001; WB1001; WBI 1001. GSK-2894512; GSK 2894512; GSK2894512; 3,5-DH4IS; tapinarof

IUPAC/Chemical Name: 3,5-Dihydroxy-4-isopropylstilbene


InChi Code: InChI=1S/C17H18O2/c1-12(2)17-15(18)10-14(11-16(17)19)9-8-13-6-4-3-5-7-13/h3-12,18-19H,1-2H3/b9-8+


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Zang YN, Jiang DL, Cai L, Chen X, Wang Q, Xie ZW, Liu Y, Zhang CY, Jing S, Chen GH, Zhang JZ, Xu L, Feng WY, Zhao LB, Fang Y. Use of a dose-response model to guide future clinical trial of benvitimod cream to treat mild and moderate psoriasis. Int J Clin Pharmacol Ther. 2016 Feb;54(2):87-95. doi: 10.5414/CP202486. PubMed PMID: 26709597.

2: Zhao L, Chen X, Cai L, Zhang C, Wang Q, Jing S, Chen G, Li J, Zhang J, Fang Y. Randomized, double-blind, placebo-controlled, multiple-dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis. J Clin Pharm Ther. 2014 Aug;39(4):418-23. doi: 10.1111/jcpt.12158. Epub 2014 Mar 27. PubMed PMID: 24673513.

3: Paul C. New topical drug development in atopic dermatitis: a place for hope. Br J Dermatol. 2012 Apr;166(4):711. doi: 10.1111/j.1365-2133.2012.10913.x. PubMed PMID: 22452438.

4: Zhao L, Zhu B, Chen X, Chen G, Chen H, Li Y, Jing S, Fang Y. Development and validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for benvitimod quantification in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Feb 15;885-886:160-5. doi: 10.1016/j.jchromb.2011.12.026. Epub 2012 Jan 9. Erratum in: J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Apr 1;891-892:113. PubMed PMID: 22281235.

5: Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012 Apr;166(4):853-60. doi: 10.1111/j.1365-2133.2011.10775.x. Epub 2012 Mar 14. PubMed PMID: 22182053.

6: Bissonnette R, Bolduc C, Maari C, Nigen S, Webster JM, Tang L, Lyle M. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012 Dec;26(12):1516-21. doi: 10.1111/j.1468-3083.2011.04332.x. Epub 2011 Nov 12. PubMed PMID: 22077962.